enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference

enGene Therapeutics Inc.

2026-Q1 EPS reported $0.44

Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
Cash & marketable securities $312.5M; expected runway into 2H 2028.
Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.
LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.
12-month CR data expected 2H 2026; CDRP program selected by FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

enGene Therapeutics Inc. reported first quarter ended January 31, 2026 results: net income net loss attributable to common shareholders was approximately $29.8 million, EPS $0.44 per share.

Period: first quarter ended January 31, 2026
Net income: net loss attributable to common shareholders was approximately $29.8 million
EPS: $0.44 per share
Result: reported results

Exact text from the filing

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

View on SEC.gov

Browse all earnings releases →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097534

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.